Project Grant HT94252410909
Award Date 9/30/24
Completion Date 9/29/28
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
- The University of California, Davis was awarded a $1,446,250 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research on "THERAPEUTIC TARGETING OF A NOVEL TUMOR-INTRINSIC SIGNALING PATHWAY FOR LETHAL PROSTATE CANCER." The award period is from August 1, 2023 to July 31, 2026. UC Davis will leverage its expertise in medical research to investigate potential medical solutions relevant to the...
- This Project Grant award of $1,801,179.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the University of California, Davis (UC Davis) focused on the "Contribution of Bone Mass and Fracture to Bone Metastasis in Prostate Cancer". The research aims to transform healthcare for military service members, veterans, and the broader public by investigating innovative medical solutions to address...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,729,963.00 to the University of California, Davis (UC Davis) to develop novel therapeutics targeting BET-mediated oncogenesis in lethal prostate cancer. The award period runs from November 1, 2025 to October 31, 2028. As a prominent public research university, UC Davis has extensive capabilities in conducting sophisticated biomedical research and...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $644,000.00 to the University of California, Davis (UC Davis) to support research on a PLZ4-targeting ultra-small DM1 nanoconjugate for bladder cancer therapy. The research aims to transform healthcare for military service members, veterans, and the broader public by developing innovative diagnostic tools, therapeutic interventions, and clinical...
- The University of California, Davis was awarded a $1,177,500 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research to target a key tumor plasticity driver in lethal prostate cancer. Through August 2021 to July 2024, UC Davis researchers will investigate medical solutions for prostate cancer on the cellular level with the aim of transforming patient care and outcomes. The...
- The federal Project Grant award of $1,008,313 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. This award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award was granted to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to conduct research on melanoma....
- The federal Project Grant award of $1,626,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by the University of California, San Francisco (UCSF) to transform healthcare for military service members, veterans, and the general public. The award, with a performance period from September 15, 2025 to September 14, 2029, will fund specialized medical research and development in areas such as cancer,...
- This Project Grant award for $810,472, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of California, Davis aimed at the development of a triple inhibitor treatment for lethal prostate cancer. The research is focused on simultaneously inhibiting the AKR1C3, COX2, and SEH enzymes, which play key roles in the progression of aggressive forms of prostate cancer. The award has a performance period...
- This Project Grant award of $636,285 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of California, Davis (UC Davis) on "TRIPLE AKR1C3/COX2/SEH INHIBITION FOR THE TREATMENT OF LETHAL PROSTATE CANCER." The funding will be used over a 3-year period from September 2023 to August 2026 to conduct basic, translational, and clinical research aimed at developing new treatments for prostate cancer, a key health...
- This federal Project Grant award of $1,041,595.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Regents of the University of California, San Francisco (UCSF) on September 1, 2024. The award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, this 3-year Melanoma Research Program Team Science Award will fund innovative and...